CD274 and cancer: The phase III KEYNOTE 590 study of pembrolizumab with chemotherapy as first-line therapy in advanced PD-L1 positive CPS ≥ 10 oesopheageal cancer is ongoing (NCT03189719) and will clarify whether the combination of chemotherapy plus ICI can improve OS in these patients over chemotherapy alone.